Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leukemia
Main Authors: Casneuf, Tineke, Adams, Homer C., van de Donk, Niels W.C.J., Abraham, Yann, Bald, Jaime, Vanhoof, Greet, Van der Borght, Koen, Smets, Tina, Foulk, Brad, Nielsen, Karl C., Rusbuldt, Joshua, Axel, Amy, Lysaght, Andrew, Ceulemans, Hugo, Stevenaert, Frederik, Usmani, Saad Z., Plesner, Torben, Avet-Loiseau, Herve, Nijhof, Inger, Mutis, Tuna, Schecter, Jordan M., Chiu, Christopher, Bahlis, Nizar J.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862054/
https://ncbi.nlm.nih.gov/pubmed/32457357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0855-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker